FreshRecalls

FDAClass II · Drug · Recalled May 6, 2026

fentaNYL Citrate Injectable Solution in 0 recall — Wells Pharma of Houston LLC

Hazard: cGMP deviations.

Class II: may cause temporary or medically reversible health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID
D-0508-2026
Brand
Wells Pharma of Houston
Classification
Class II
Units affected
50 syringes
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Description

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.

Affected products

Companies & origin

Recalling firm location
Houston, TX, United States
Firm address
9265 Kirby Dr, 77054-2520

Identifying details (verbatim from the notice)

Product codes / lots
Lot 020226202150202, Exp Date 05/05/2026.
Distribution
U.S. Nationwide.
Firm notified the public via
Letter
FDA event ID
98694
Recall initiated
April 1, 2026
FDA classified
April 28, 2026
FDA report date
May 6, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 24, 2026 at 12:00 AM UTC.

Report a data error on this page